1139PSensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
ConclusionsERCC1 expression is a well-established biomarker for cisplatin resistance. Our study demonstrates that wtHRASov tumours represent a distinctive entity that strongly express ERCC1 and can be resensitized to cisplatin by tipifarnib.Legal entity responsible for the studyThe authors.FundingKura Oncology.DisclosureT. Rampias: Research grant / Funding (institution): Kura Oncology Company. All other authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
248PPAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis
ConclusionsHER2-E subtype identifies patients with a higher likelihood of achieving a pCR following anti-HER2-based NAT, with or without CT. In the latter case, albeit limited by small casuistry, the association seems stronger in HR+ tumors. This suggests that strategies to escalate or de-escalate systemic therapy in HER2+ tumors would benefit from incorporating intrinsic subtypes.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureF. Schettini: Travel / Accommodation / Expenses: Pfizer and Celgene. T. Pascual: Advisory / Consultancy: Roche. P.F. Conte: Honoraria (self): BMS, Roc...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1587TiPCANOPY phase III program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
AbstractBackgroundThe presence of inflammatory mediators in the tumor microenvironment may have pro or antitumorigenic effects. The cytokine interleukin-1 β (IL-1β) affects multiple aspects of the tumor microenvironment promoting carcinogenesis, tumor invasiveness, and immunosuppression. Canakinumab is a human monoclonal antibody with high affinity and specificity for IL-1β. Results of the phase III Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) have shown that IL-1β inhibition with canakinumab was associated with reduced lung cancer incidence and mortality, providing a rationale to investigate the po...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
12PEGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models
ConclusionsThe results indicate PD-L1 expression can be altered by manipulation of EGFR activity in HER2+ breast cancer cell line models. The development of targeted therapy resistance can interfere with the ability of EGFR to impact PD-L1 levels. Further examination of EGFR and PD-L1 is warranted in HER2+ breast cancer models.Legal entity responsible for the studyThe authors.FundingCancer Clinical Research Trust.DisclosureA. Canonici: Research grant/Funding (institution): Boehringer Ingelheim. J. Crown: Full/Part-time employment: OncoMark; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research g...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1140PA single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
ConclusionsIn this phase IIIb trial, nivolumab confirmed the safety and efficacy profile of the registration trial. Experiencing any grade TR AE revealed to be a favorable prognostic factor, as possible expression of effective immune response.Legal entity responsible for the studyGONO group.FundingBristol Myers-Squibb.DisclosureP. Bossi: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BMS; Advisory / Consultancy: Angelini; Advisory / Consultancy: MSD; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Voluntis. M.C. Merlano: Honoraria (self), consultancy or A.B.: Bristol M.S.; Honoraria (self), cons...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
249PAssessment of CPS+EG, neo-bioscore and modified neo-bioscore in breast cancer patients treated with preoperative systemic therapy: A multicenter cohort study
ConclusionsThe modified Neo-Bioscore could circumvent the limitation of CPS+EG or Neo-Bioscore. The access of appropriate treatment should be incorporated into the existing staging systems for more refined prognosis prediction.Clinical trial identificationThe trial protocol number: NCT03437837 Release date: February 19, 2018.Legal entity responsible for the studyXuening Duan AND Yimin Cui.FundingNational Key Research and Development Program of China.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
468PA phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours
ConclusionsThis study is continuing to enroll pts and will identify the recommended dose of ADCT-601. Updated results, including pharmacokinetic data, will be presented at the meeting.Clinical trial identificationNIH (https://clinicaltrials.gov/ct2/show/NCT03700294) October 9, 2018.Editorial acknowledgementEditorial support was provided by Sindhu Doppalapudi and Becky Salisbury at Fishawack Communications Ltd, funded by ADC Therapeutics Ltd.Legal entity responsible for the studyADC Therapeutics.FundingADC Therapeutics.DisclosureA.W. Tolcher: Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Advisory /...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
13PThe impact of cortisol on immune cells and its effect on cancer-immune cells co-culture in a 3D spheroid of ovarian cancer
ConclusionsIn conclusion, both chronic stress and acute exposure to cortisol can increase DNA damage in splenocytes and T lymphocytes reducing their infiltration into cancer spheroids. This data may have impact for patient with ovarian cancer experiencing extreme stress.Legal entity responsible for the studyThe author.FundingHas not received any funding.DisclosureThe author has declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
250PThe concordance of treatment decision guided by oncotype and the PREDICT tool in early stage breast cancer
ConclusionsCompared to PREDICT, using Oncotype in node negative, ER positive disease is expected to change clinical decision in a quarter of patients. The concordance is influenced by pathological features. The use of Oncotype may not be necessary for clinically very low risk patients.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureH. Goldvaser: Honoraria (self): Roche. R. Yerushalmi: Honoraria (self): Roche; Honoraria (self): Medison; Honoraria (self): AstraZeneca; Honoraria (self): Novartis; Honoraria (self): Teva. M. Sarfaty: Honoraria (self): Roche; Honoraria (self): MSD;...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1588TiPThe elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer
AbstractBackgroundNon-small cell lung cancer (NSCLC) is one of the commonest disease worldwide and the leading cause of cancer-related death. Incidence increases with age and reaches a peak in senility, when patients ’ (pts) comorbidities may limit the efficacy of treatments. At this time, no homogeneous indications are available for elderly NSCLC pts and the optimization of treatment, with the lowest side effects, is still an unmet need, also after the introduction of innovative drugs. The ribonucleotide redu ctase catalytic subunit M1(RRM1), the DNA-excision repair protein ERCC1 and the thymidylate synthetase (TS) are ...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1141PLong-term results of phase II trial of reduced modified clinical target volume in low-risk nasopharyngeal carcinoma treated with intensity modulated radiotherapy
ConclusionsReduced CTV margins and corresponding doses results in optimal long-term tumour control, with minimal late adverse events.Clinical trial identificationNCT03839602.Legal entity responsible for the studyChong Zhao.FundingNational Natural Science Foundation of China [No. 81872469]; Science and Technology Project of Guangdong Province [No. 2014A020212433].DisclosureM.L.K. Chua: Honoraria (institution), Advisory / Consultancy: Janssen, Astellas, Varian, Ferring Singapore and AstraZeneca; Research grant / Funding (institution), Structured research agreement/Research funding - Ferring Singapore, GenomeDx Biosciences, V...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
14PApplication of sonoporation to increase anticancer drug efficacy in 2D and 3D NSCLC cell cultures
ConclusionsUS is a promising physical method to enhance anticancer drug efficacy, especially into 3D cell cultures. However, there is a lack of evidence about its efficacy and further studies are needed.Legal entity responsible for the studyThe authors.FundingLithuanian University of Health Sciences; Kaunas University of Technology.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
469PSafety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti ‐PD‐L1 antibody, in patients (pts) with advanced cancers
ConclusionsCosibelimab has demonstrated a safe and well-tolerated safety profile with evidence of durable anti ‐tumor activity in several advanced cancers, and linear PK. Cosibelimab is being further evaluated in multiple tumor-specific expansion cohorts. Updated results will be presented.Clinical trial identificationNCT03212404.Legal entity responsible for the studyCheckpoint Therapeutics, Inc.FundingCheckpoint Therapeutics, Inc.DisclosureP.R. Clingan: Research grant / Funding (institution): Merck Sharp& Dohme Corp; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Eli Lilly; Re...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
251PInfluence of first treatment delay on survival among breast cancer subtypes
ConclusionsWaiting 60 days to initiate treatment was associated with a significantly worse overall survivall among triple negative and HER2 BC. We consider it of importance to offer early treatment to aggressive BC subtypes.Legal entity responsible for the studyREDISSEC-CAMISS Group-(Research Network in Health Services in Chronic Diseases).FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1589TiPKEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non –small cell lung cancer (NSCLC)
AbstractBackgroundKEYNOTE-495 is a randomized, open-label, phase II trial (NCT03516981) evaluating the clinical activity and safety of pembrolizumab (pembro)-based combination (combo) therapy in patients (pts) with treatment-naive, advanced NSCLC in biomarker-defined response groups. This biomarker-based approach is based on 2 validated, independent, next-generation biomarkers (T cell –inflamed gene expression profile [GEP] and tumor mutational burden [TMB]) and can help determine the differential efficacy of pembro-based combo therapy, based on the composite biomarker profile, and inform precision immunotherapy in the f...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
